Exhibit 10.3


BOARD OF DIRECTORS AGREEMENT


 


This Board of Directors Agreement (“Agreement”)
made as of October 27, 2008 by and between Apollo Medical Holdings, Inc., with its principal place of business at 1010 N. Central
Avenue, Suite 201, Glendale, California  91202 (“ApolloMed”) and Suresh Nihalani, with an address of 7352
Zaharias Court, Moorpark, CA- 93021, (the “Director”) provides for director services, according to the following terms
and conditions:


 


	I.	Services Provided


 


ApolloMed agrees to engage the Director to serve as a member
of the Board of Directors of ApolloMed and to provide those services required of a director under ApolloMed’s Certificate
of Incorporation and Bylaws, as both may be amended from time, to time (“Articles and Bylaws”) and under the General
Corporation Law of Delaware, the federal securities laws and other state and federal laws and regulations, as applicable.


 


	II.	Nature of Relationship


 


The Director is an independent contractor and will not be deemed
an employee of ApolloMed for purposes of employee benefits, income tax withholding, F.I.C.A. taxes, unemployment benefits or otherwise. 
The Director shall not enter into any agreement or incur any obligations on ApolloMed’s behalf.


 


ApolloMed will supply, at no cost to the Director:  periodic
briefings on the business, director packages for each board and committee meeting, copies of minutes of meetings and any other
materials that are required under ApolloMed’s Articles and Bylaws or the charter of any committee of the board on which the
Director serves and any other materials which may, by mutual agreement, be necessary for performing the services requested under
this Agreement.


 


	III.	Director’s Warranties


 


The Director warrants that no other party has exclusive rights
to his services in the specific areas in which AppoloMed is conducting business and that the Director is in no way compromising
any rights or trust between any other party and the Director or creating a conflict of interest as a result of his participation
on the Board of Directors of ApolloMed.  The Director also warrants that so long as the Director serves on the board of the
directors of ApolloMed, the Director will not enter into another agreement that will create a conflict of interest with this Agreement. 
The Director further warrants that he will comply with all applicable state and federal laws and regulations, as applicable, including
Sections 10 and 16 of the Securities and Exchange Act of 1934.


 


Throughout the term of this Agreement, the Director agrees he
will not, without obtaining ApolloMed’s prior written consent, directly or indirectly engage or prepare to engage in any
activity in competition with any ApolloMed business or product, including products in the development stage, accept employment
or provide services to (including service as a member of a board of directors), or establish a business in competition with ApolloMed.


 


	IV.	Compensation


 


	A.	Cash Fee


 


During the term of this Agreement, ApolloMed shall pay the Director
a nonrefundable fee of $1,000 per board of director meeting in consideration for the Director providing the services described
in Section I which shall compensate him for all time spent preparing for, travelling to (if applicable) and attending board of
director meetings; provided, however, that if any board meetings or duties require out-of-town travel time, such additional travel
time may be billed at the rate set forth in subparagraph C of Section IV below.  This cash fee may be revised by action of
ApolloMed’s Board of Directors from time to time.  Such revision shall be effective as of the date specified in the
resolution for payments not yet earned and need not be documented by an amendment to this Agreement.


 



     

     

    

 


 


	B.	Equity Compensation


 


Issuance of Shares.    Upon the execution
and delivery of this Agreement, ApolloMed shall issue to the Director (or designee of the Director) a restricted stock award of
400,000 shares of ApolloMed’s  common stock (collectively, the “Shares”).  The purchase price
for the Shares will be $0.0001 per Share.  Pursuant to the request of the Director, all of the Shares shall be issued
in the name of “The Shining Star Family Trust” and the Shares that have not been released from Escrow (as defined herein
below) may not be sold, pledged, hypothecated or otherwise transferred to any other person.  All certificates representing
the Shares shall bear a legend regarding the fact that the Shares are not registered under the Securities Act of 1933, as amended
(the “Securities Act”), and none of the Shares may be sold, pledged, hypothecated or otherwise transferred without
compliance with Federal and applicable state securities laws.


 


Escrow of Shares .  Certificates evidencing
all Shares shall be placed in escrow maintained at all times by the Company (“Escrow”).  Provided this Agreement
has not been previously terminated, on the last day of each month during the term of this Agreement, 1/36 th of the
total number of Shares shall be promptly released from Escrow by ApolloMed to the Director.  If the Agreement is terminated
prior to the end of any calendar month during the term of this Agreement, for any reason or for no reason, and regardless of the
party who initiated the termination, the Director shall receive a pro-rata number of Shares for that calendar month based upon
the actual number of days elapsed prior to the date of termination.  Except as set forth in the immediately preceding
sentence, upon the termination of this Agreement, for any reason or for no reason, and regardless of the party who initiated the
termination, no additional Shares shall be released from Escrow.  Unless otherwise agreed to by ApolloMed and the Director
in writing, if this Agreement remains in effect for more than 36 months, no additional shares shall be issued to the Director hereunder.   Notwithstanding
anything contained herein to the contrary, the Shares shall be issued and released from Escrow only in full compliance with Federal
and all applicable state securities laws and the Director shall cooperate with all requests of ApolloMed in order to comply with
all such laws as may be reasonably requested by the Company or its counsel.  The Shares do not carry registration rights
and the Director has no right to compel the registration of any of the Shares, either before or after they are released from Escrow.  Additionally,
the Director covenants and agrees to be bound by all standard policies and guidelines applicable to the other directors and executive
officers of ApolloMed with respect to transaction in the Shares, including without limitation the terms and conditions of any insider
trading policy, code of ethics, corporate governance guidelines, or similar policies, codes and guidelines adopted by the Board
of Directors of ApolloMed from time to time.


 


Repurchase Obligation .  Upon the termination
of this Agreement, for any reason or for no reason, and regardless of the party who initiated the termination, any Shares which
AppoloMed is not yet obligated to released from Escrow (“Repurchased Shares”) shall be repurchased by the Company at
a price of $0.0001 per Repurchased Share (the “Repurchase Per Share Price”).  ApolloMed shall remit its check
to the Director within 10 business days following such termination in the full amount of the Repurchase Per Share Price multiplied
by the number of Repurchased Shares.  For example, if there were 100,000 Shares remaining in Escrow upon the termination
of this Agreement, ApolloMed would repurchase the 100,000 Shares by remitting its check to the Director in the amount of 100,000
x $0.0001 = $10.00.


 


	C.	Additional Payments


 


To the extent services described in Section I require out-of-town
trips, such additional travel time may be charged at the rate of $1,200 per day or pro rated portion thereof.   This
rate may be revised by action of ApolloMed’s Board of Directors from time to time for payments not yet earned.  Such
revision shall be effective as of the date specified in the resolution and need not be documented by an amendment to this Agreement.


 


 


2



    	 



    	 



    

 


 


	D.	Payment


 


Cash fees shall be made quarterly in cash in advance on the
first day of each accounting quarter.  Additional payments shall be made in arrears.  No invoices need be submitted by
the Director for payment of the cash fee.  Invoices for additional payments under subparagraph C of Section IV, above, shall
be submitted by the Director. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.


 


	E.	Expenses


 


ApolloMed will reimburse the Director for reasonable expenses
approved in advance, such approval not to be unreasonably withheld.  Invoices for expenses, with receipts attached, shall
be submitted. Such invoices must be approved by ApolloMed’s Chief Executive Officer as to form and completeness.


 


	V.	Indemnification and Insurance


 


ApolloMed will execute an indemnification agreement in favor
of the Director substantially in the form of the agreement attached hereto as Exhibit B (the “Indemnification Agreement”). 
In addition, so long as ApolloMed’s indemnification obligations exist under the Indemnification Agreement, ApolloMed shall
provide the Director with directors and officers liability insurance coverage in the amounts specified in the Indemnification Agreement.


 


	VI.	Term of Agreement


 


This Agreement shall be in effect from the date hereof through
the last date of the Director’s current term as a member of ApolloMed’s Board of Directors.  This Agreement shall
be automatically renewed on the date of the Director’s reelection as a member of ApolloMed’s Board of Director’s
for the period of such new term unless the Board of Directors determines not to renew this Agreement.   Any amendment
to this Agreement must be approved by a written action of ApolloMed’s Board of Directors.  Amendments to Section IV
Compensation hereof do not require the Director’s consent to be effective.


 


	VII.	Termination


 


This Agreement shall automatically terminate upon the death
of the Director or upon his resignation or removal from, or failure to win election or reelection to, the ApolloMed Board of Directors.  This
Agreement may be terminated at any time, with or without cause, by either ApolloMed or the Director.


 


In the event of any termination of this Agreement, the Director
agrees to return or destroy any materials transferred to the Director under this Agreement except as may be necessary to fulfill
any outstanding obligations hereunder.  The Director agrees that ApolloMed has the right of injunctive relief to enforce this
provision.


 


ApolloMed’s and the Director’s continuing obligations
hereunder in the event of such termination shall be subject to the terms of Section XIV hereof.


 


	VIII. 	Limitation of Liability


 


Under no circumstances shall ApolloMed be liable to the Director
for any consequential damages claimed by any other party as a result of representations made by the Director with respect to ApolloMed
which are materially different from any to those made in writing by ApolloMed.


 


 


3



    	 



    	 



    

 


 


Furthermore, except for the maintenance of confidentiality,
neither party shall be liable to the other for delay in any performance, or for failure to render any performance under this Agreement
when such delay or failure is caused by Government regulations (whether or not valid), fire, strike, differences with workmen,
illness of employees, flood, accident, or any other cause or causes beyond reasonable control of such delinquent party.


 


	IX.	Confidentiality


 


The Director agrees to sign and abide by ApolloMed’s Director
Proprietary Information and Inventions Agreement, a copy of which is attached hereto as Exhibit A.


 


	X.	Resolution of Dispute


 


Any dispute regarding the agreement (including without limitation
its validity, interpretation, performance, enforcement, termination and damages) shall be determined in accordance with the laws
of the State of California, the United States of America.  Any action under this paragraph shall not preclude any party hereto
from seeking injunctive or other legal relief to which each party may be entitled.


 


	XI.	Sole Agreement


 


This Agreement (including agreements executed in substantially
in the form of the exhibits attached hereto) supersedes all prior or contemporaneous written or oral understandings or agreements,
and may not be added to, modified, or waived, in whole or in part, except by a writing signed by the party against whom such addition,
modification or waiver is sought to be asserted.


 


	XII.	Assignment


 


This Agreement and all of the provisions hereof shall be binding
upon and insure to the benefit of the parties hereto and their respective successors and permitted assigns and, except as otherwise
expressly provided herein, neither this Agreement, nor any of the rights, interests or obligations hereunder shall be assigned
by either of the parties hereto without the prior written consent of the other party.


 


	XIII.	Notices


 


Any and all notices, requests and other communications required
or permitted hereunder shall be in writing, registered mail or by facsimile, to each of the parties at the addresses set forth
above or the numbers set forth below:


The Director:


 


	ApolloMed:	1010 N. Central Avenue, Suite 201
	 	Glendale, CA  91202


 


Any such notice shall be deemed given when received and notice
given by registered mail shall be considered to have been given on the tenth (10th) day after having been sent in the manner provided
for above.


 


 


4





	 



    	 



    

 


 


	XIV.	Survival of Obligations


 


Notwithstanding the expiration of termination of this Agreement,
neither party hereto shall be released hereunder from any liability or obligation to the other which has already accrued as of
the time of such expiration or termination (including, without limitation, ApolloMed’s obligation to make any fees and expense
payments required pursuant to Section IV and/or AppoloMed’s indemnification and insurance obligations set forth in Section
V hereof) or which thereafter might accrue in respect of any act or omission of such party prior to such expiration or termination.


 


	XV.	Attorneys’ Fees


 


If any legal action or other proceeding is brought for the enforcement
of this Agreement, or because of a dispute, breach or default in connection with any of the provisions hereof, the successful or
prevailing party (including a party successful or prevailing in defense) shall be entitled to recover its actual attorneys’
fees and other costs incurred in that action or proceeding, in addition to any other relief to which it may be entitled .


 


	XV.	Severability


 


Any provision of this Agreement which is determined to be invalid
or unenforceable shall not affect the remainder of this Agreement, which shall remain in effect as though the invalid or unenforceable
provision had not been included herein, unless the removal of the invalid or unenforceable provision would substantially defeat
the intent, purpose or spirit of this Agreement.


 


IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed as of the date first written above.


 


	Director:	 	Apollo Medical Holdings, Inc.
	 	 	 
	Signature: /s/ Suresh Nihalani	 	Signature: /s/ Warren Hosseinion
	 	 	 
	Print Name:   Suresh Nihalani        	 	Print Name: Warren Hosseinion, M.D.
	 	 	 
	 	 	Title: Chief Executive Officer


 


 


5



    	 



    	 



    

 


 


EXHIBIT A


 


  BOARD OF DIRECTORS PROPRIETARY
INFORMATION AGREEMENT


 


THIS BOARD OF DIRECTORS PROPRIETARY INFORMATION AGREEMENT
(“Agreement”) is made and entered into this 27th day of October, 2008 by and between APOLLO MEDICAL MANAGEMENT,
INC ., a Delaware corporation (“ApolloMed”), and Suresh Nihalani (the “Director”).


 


RECITALS


 


WHEREAS, the Director has been elected to serve on the Board
of Directors of ApolloMed;


 


WHEREAS, the parties desire to assure the confidential status
of the information which may be disclosed by ApolloMed to the Director in connection with the Director serving on ApolloMed’s
Board of Directors;


 


 NOW THEREFORE, in reliance upon and in consideration of
the following undertaking, the parties agree as follows:


 


AGREEMENT


 


      1.      
Subject to the limitations set forth in Paragraph 2, all information disclosed by ApolloMed to the Director shall be deemed to
be "Proprietary Information".  In particular, Proprietary Information shall be deemed to include any information,
process, technique, algorithm, program, design, drawing, formula or test data relating to any research project, work in process,
future development, engineering, manufacturing, marketing, servicing, financing or personnel matter relating to ApolloMed, its
present or future products, sales, suppliers, customers, employees, investors, or business, whether or oral, written, graphic or
electronic form.


 


      2.      
The term "Proprietary Information" shall not be deemed to include the following information: (i) information which is
now, or hereafter becomes, through no breach of this Agreement on the part of the Director, generally known or available to the
public; (ii) is known by the Director at the time of receiving such information; (iii) is hereafter furnished to the Director by
a third party, as a matter of right and without restriction on disclosure; or (iv) is the subject of a written permission to disclose
provided by ApolloMed.


 


      3.      
The Director shall maintain in trust and confidence and not disclose to any third party or use for any unauthorized purpose any
Proprietary Information received from ApolloMed.  The Director may use such Proprietary Information only to the extent required
to accomplish the purposes of his position as a Director of ApolloMed.  The Director shall not use Proprietary Information
for any purpose or in any manner which would constitute a violation of any laws or regulations, including without limitation the
export control laws of the United States.  No other rights of licenses to trademarks, inventions, copyrights, or patents are
implied or granted under this Agreement.


 


      4.      
Proprietary Information supplied shall not be reproduced in any form except as required to accomplish the intent of this Agreement.


 


      5.      
The Director represents and warrants that he shall protect the Proprietary Information received with at least the same degree of
care used to protect his own Proprietary Information from unauthorized use or disclosure. 


 


      6.      
All Proprietary Information (including all copies thereof) shall remain in the property of ApolloMed, and shall be returned to
ApolloMed (or destroyed) after the Director's need for it has expired, or upon request of ApolloMed, and in any event, upon the
termination of that certain Board of Directors Agreement, of even date herewith, between ApolloMed and the Director (the “Director
Agreement”).


 


 


6



    	 



    	 



    

 


 


      7.      
Notwithstanding any other provision of this Agreement, disclosure of Proprietary Information shall not be precluded if such disclosure:


 


(a)   is in response to a valid order of a court or
other governmental body of the United States or any political subdivision thereof; provided, however, that the Director shall first
have given ApolloMed notice of the Director’s receipt of such order and ApolloMed shall have had an opportunity to obtain
a protective order requiring that the Proprietary Information so disclosed be used only for the purpose for which the order was
issued;


 


(b)   is otherwise required by law; or


 


(c)   is otherwise necessary to establish rights or
enforce obligations under this Agreement, but only to the extent that any such disclosure is necessary.


 


      8.      
Subject to the terms of this Paragraph, this Agreement shall continue in full force and effect during the term of the Director
Agreement.  This Agreement may be terminated at any time upon thirty (30) days written notice to the other party. 
The termination of this Agreement shall not relieve the Director of the obligations imposed by Paragraphs 3, 4, 5 and 11 of this
Agreement with respect to Proprietary information disclosed prior to the effective date of such termination and the provisions
of these Paragraphs shall survive the termination of this Agreement for a period of eighteen (18) months from the date of such
termination.


 


      9.      This
Agreement shall be governed by the laws of the State of California as those laws are applied to contracts entered into and to be
performed entirely in California by California residents.


 


      10.     
This Agreement contains the final, complete and exclusive agreement of the parties relative to the subject matter hereof and may
not be changed, modified, amended or supplemented except by a written instrument signed by both parties.


 


      11.     
Each party hereby acknowledges and agrees that in the event of any breach of this Agreement by the Director, including, without
limitation, an actual or threatened disclosure of Proprietary Information without the prior express written consent of ApolloMed,
ApolloMed will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate
compensation for, such injury.  Accordingly, each party hereby agrees that ApolloMed shall be entitled to specific performance
of the Director's obligations under this Agreement, as well as such further injunctive relief as may be granted by a court of competent
jurisdiction.


 


	Director:	 	Apollo Medical Management, Inc.
	 	 	 
	Signature: /s/ Suresh Nihalani	 	Signature:  /s/ Warren Hosseinion
	 	 	 
	Print Name:  Suresh Nihalani	 	Print Name:  Warren Hosseinion, M.D.
	 	 	 
	 	 	Title:  Chief Executive Officer


 


 


7



    	 



    	 



    

 


 


EXHIBIT B


 


INDEMNIFICATION AGREEMENT


 


INDEMNIFICATION AGREEMENT (this “Agreement”)
dated as of October 27, 2008, by and among APOLLO MEDICAL MANAGEMENT, INC., a Delaware corporation (the “Company”)
and the indemnitees listed on the signature pages hereto (individually, as “Indemnitee” and, collectively, the “Indemnitees”).


 


RECITALS


 


A.           The
Company and Indemnitees recognize the continued difficulty in obtaining liability insurance for its directors, officers, employees,
stockholders, controlling persons, agents and fiduciaries, the significant increases in the cost of such insurance and the general
reductions in the coverage of such insurance.


 


B.           The
Company and Indemnitees further recognize the substantial increase in corporate litigation in general, which subjects directors,
officers, employees, controlling persons, stockholders, agents and fiduciaries to expensive litigation risks at the same time as
the availability and coverage of liability insurance has been severely limited.


 


C.           The
Indemnitees do not regard the current protection available as adequate under the present circumstances, and Indemnitees and other
directors, officers, employees, stockholders, controlling persons, agents and fiduciaries of the Company may not be willing to
serve in such capacities without additional protection.


 


D.           The
Company (i) desires to attract and retain highly qualified individuals and entities, such as Indemnitees, to serve the Company
and, in part, in order to induce each Indemnitee to be involved with the Company and (ii) wishes to provide for the indemnification
and advancing of expenses to each Indemnitee to the maximum extent permitted by law.


 


E.           In
view of the considerations set forth above, the Company desires that each Indemnitee be indemnified by the Company as set forth
herein.


 


NOW, THEREFORE, the Company and each Indemnitee
hereby agree as follows:


 


 


8



    	 



    	 



    

 


 


1.        Indemnification


 


a.       
Indemnification of Expenses .  The Company shall indemnify and hold harmless each Indemnitee (including its respective
directors, officers, partners, former partners, members, former members, employees, agents and spouse, as applicable) and each
person who controls any of them or who may be liable within the meaning of Section 15 of the Securities Act of 1933, as amended
(the “Securities Act”), or Section 20 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
to the fullest extent permitted by law if such Indemnitee was or is or becomes a party to or witness or other participant in, or
is threatened to be made a party to or witness or other participant in, any threatened, pending or completed action, suit, proceeding
or alternative dispute resolution mechanism, or any hearing, inquiry or investigation that such Indemnitee believes might lead
to the institution of any such action, suit, proceeding or alternative dispute resolution mechanism, whether civil, criminal, administrative,
investigative or other (hereinafter a “Claim”) by reason of (or arising in part or in whole out of) any event or occurrence
related to the fact that Indemnitee is or was or may be deemed a director, officer, stockholder, employee, controlling person,
agent or fiduciary of the Company, or any subsidiary of the Company, or is or was or may be deemed to be serving at the request
of the Company as a director, officer, stockholder, employee, controlling person, agent or fiduciary of another corporation, partnership,
limited liability company, joint venture, trust or other enterprise, or by reason of any action or inaction on the part of such
Indemnitee while serving in such capacity including, without limitation, any and all losses, claims, damages, expenses and liabilities,
joint or several (including any investigation, legal and other expenses incurred in connection with, and any amount paid in settlement
of, any action, suit, proceeding or any claim asserted) under the Securities Act, the Exchange Act or other federal or state statutory
law or regulation, at common law or otherwise or which relate directly or indirectly to the registration, purchase, sale or ownership
of any securities of the Company or to any fiduciary obligation owed with respect thereto or as a direct or indirect result of
any Claim made by any stockholder of the Company against an Indemnitee and arising out of or related to any round of financing
of the Company (including but not limited to Claims regarding non-participation, or non-pro rata participation, in such round by
such stockholder), or made by a third party against an Indemnitee based on any misstatement or omission of a material fact by the
Company in violation of any duty of disclosure imposed on the Company by federal or state securities or common laws (hereinafter
an “Indemnification Event”) against any and all expenses (including attorneys’ fees and all other costs, expenses
and obligations incurred in connection with investigating, defending a witness in or participating in (including on appeal), or
preparing to defend, be a witness in or participate in, any such action, suit, proceeding, alternative dispute resolution mechanism,
hearing, inquiry or investigation), judgments, fines, penalties and amounts paid in settlement (if, and only if, such settlement
is approved in advance by the Company, which approval shall not be unreasonably withheld) of such Claim and any federal, state,
local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement (collectively,
hereinafter “Expenses”), including all interest, assessments and other charges paid or payable in connection with or
in respect of such Expenses.  Such payment of Expenses shall be made by the Company as soon as practicable but in any
event no later than ten (10) days after written demand by the Indemnitee therefor is presented to the Company.


 


b.       
Reviewing Party .  Notwithstanding the foregoing, (i) the obligations of the Company under Section 1(a) shall
be subject to the condition that the Reviewing Party (as described in Section 10(e) hereof) shall not have determined (in a written
opinion, in any case in which the Independent Legal Counsel referred to in Section 1(e) hereof is involved) that Indemnitee would
not be permitted to be indemnified under applicable law, and (ii) each Indemnitee acknowledges and agrees that the obligation of
the Company to make an advance payment of Expenses to Indemnitee pursuant to Section 2(a) (an “Expense Advance”) shall
be subject to the condition that, if, when and to the extent that the Reviewing Party determines that Indemnitee would not be permitted
to be so indemnified under applicable law, the Company shall be entitled to be reimbursed by Indemnitee (who hereby agrees to reimburse
the Company) for all such amounts theretofore paid; provided, however, that if Indemnitee has commenced or thereafter commences
legal proceedings in a court of competent jurisdiction to secure a determination that Indemnitee should be indemnified under applicable
law, any determination made by the Reviewing Party that Indemnitee would not be permitted to be indemnified under applicable law
shall not be binding and Indemnitee shall not be required to reimburse the Company for any Expense Advance until a final judicial
determination is made with respect thereto (as to which all rights of appeal therefrom have been exhausted or lapsed).  Indemnitee’s
obligation to reimburse the Company for any Expense Advance shall be unsecured and no interest shall be charged thereon.  If
there has not been a Change in Control (as defined in Section 10(c) hereof), the Reviewing Party shall be selected by the Board
of Directors, and if there has been such a Change in Control (other than a Change in Control which has been approved by a majority
of the Company’s Board of Directors who were directors immediately prior to such Change in Control), the Reviewing Party
shall be the Independent Legal Counsel referred to in Section 1(e) hereof.  If there has been no determination by the
Reviewing Party or if the Reviewing Party determines that Indemnitee substantively would not be permitted to be indemnified in
whole or in part under applicable law, Indemnitee shall have the right to commence litigation seeking an initial determination
by the court or challenging any such determination by the Reviewing Party or any aspect thereof, including the legal or factual
bases therefor, and the Company hereby consents to service of process and to appear in any such proceeding.  Any determination
by the Reviewing Party otherwise shall be conclusive and binding on the Company and Indemnitee.


 


 


9



    	 



    	 



    

 


 


c.        
Contribution .  If the indemnification provided for in Section 1(a) above for any reason is held by a court of
competent jurisdiction to be unavailable to an Indemnitee in respect of any losses, claims, damages, expenses or liabilities referred
to therein, then the Company, in lieu of indemnifying such Indemnitee thereunder, shall contribute to the amount paid or payable
by such Indemnitee as a result of such losses, claims, damages, expenses or liabilities (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company and the Indemnitee, or (ii) if the allocation provided by clause (i) above
is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to
in clause (i) above but also the relative fault of the Company and the Indemnitee in connection with the action or inaction which
resulted in such losses, claims, damages, expenses or liabilities, as well as any other relevant equitable considerations.  In
connection with the registration of the Company’s securities, the relative benefits received by the Company and the Indemnitee
shall be deemed to be in the same respective proportions that the net proceeds from the offering (before deducting expenses) received
by the Company and the Indemnitee, in each case as set forth in the table on the cover page of the applicable prospectus, bear
to the aggregate public offering price of the securities so offered.  The relative fault of the Company and the Indemnitee
shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the Company or the Indemnitee and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.


 


The Company and the Indemnitee agree that
it would not be just and equitable if contribution pursuant to this Section 1(c) were determined by pro rata or per capita allocation
or by any other method of allocation which does not take account of the equitable considerations referred to in the immediately
preceding paragraph.  In connection with the registration of the Company’s securities, in no event shall Indemnitee
be required to contribute any amount under this Section 1(c) in excess of the lesser of (i) that proportion of the total of such
losses, claims, damages or liabilities indemnified against equal to the proportion of the total securities sold under such registration
statement which is being sold by such Indemnitee or (ii) the proceeds received by such Indemnitee from its sale of securities under
such registration statement.  No person found guilty of fraudulent misrepresentation (within the meaning of Section 11(f)
of the Securities Act) shall be entitled to contribution from any person who was not found guilty of such fraudulent misrepresentation.


 


d.        
Survival Regardless of Investigation .  The indemnification and contribution provided for in this Section 1 will
remain in full force and effect regardless of any investigation made by or on behalf of the Indemnitee or any officer, director,
employee, agent or controlling person of the Indemnitee.


 


e.        Change
in Control . The Company agrees that if there is a Change in Control of the Company (other than a Change in Control which has
been approved by a majority of the Company’s Board of Directors who were directors immediately prior to such Change in Control)
then, with respect to all matters thereafter arising concerning the rights of Indemnitee to payments of Expenses under this Agreement
or any other agreement or under the Company’s Certificate of Incorporation, as amended (the “Certificate”), or
Bylaws as now or hereafter in effect, Independent Legal Counsel (as defined in Section 10(d) hereof) shall be selected by the Indemnitee
and approved by the Company (which approval shall not be unreasonably withheld). Such counsel, among other things, shall render
its written opinion to the Company and Indemnitee as to whether and to what extent Indemnitee would be permitted to be indemnified
under applicable law. The Company agrees to abide by such opinion and to pay the reasonable fees of the Independent Legal Counsel
referred to above and to fully indemnify such counsel against any and all expenses (including attorneys’ fees), claims, liabilities
and damages arising out of or relating to this Agreement or its engagement pursuant hereto.


 


f.       
Mandatory Payment of Expenses .  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee
has been successful on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice, in
the defense of any action, suit, proceeding, inquiry or investigation referred to in Section 1(a) hereof or in the defense of any
claim, issue or matter therein, each Indemnitee shall be indemnified against all Expenses incurred by such Indemnitee in connection
herewith.


 


 


10



    	 



    	 



    

 


 


2.        Expenses;
Indemnification Procedure.


 


a.       
Advancement of Expenses .  The Company shall advance all Expenses incurred by Indemnitee.  The advances
to be made hereunder shall be paid by the Company to Indemnitee as soon as practicable but in any event no later than fifteen (15)
days after written demand by such Indemnitee therefor to the Company.


 


b.       
Notice/Cooperation by Indemnitee .  Indemnitee shall give the Company notice as soon as practicable of any Claim
made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be
directed to the Chief Executive Officer of the Company at the address shown on the signature page of this Agreement (or such other
address as the Company shall designate in writing to Indemnitee).


 


c.       
No Presumptions; Burden of Proof .  For purposes of this Agreement, the termination of any Claim by judgment,
order, settlement (whether with or without court approval) or conviction, or upon a plea of nolo contendere, or its equivalent,
shall not create a presumption that Indemnitee did not meet any particular standard of conduct or have any particular belief or
that a court has determined that indemnification is not permitted by applicable law.  In addition, neither the failure
of the Reviewing Party to have made a determination as to whether Indemnitee has met any particular standard of conduct or had
any particular belief, nor an actual determination by the Reviewing Party that Indemnitee has not met such standard of conduct
or did not have such belief, prior to the commencement of legal proceedings by Indemnitee to secure a judicial determination that
Indemnitee should be indemnified under applicable law, shall be a defense to Indemnitee’s claim or create a presumption that
Indemnitee has not met any particular standard of conduct or did not have any particular belief.  In connection with
any determination by the Reviewing Party or otherwise as to whether Indemnitee is entitled to be indemnified hereunder, the burden
of proof shall be on the Company to establish that Indemnitee is not so entitled.


 


d.       
Notice to Insurers .  If, at the time of the receipt by the Company of a notice of a Claim pursuant to Section
2(b) hereof, the Company has liability insurance in effect which may cover such Claim, the Company shall give prompt written notice
of the commencement of such Claim to the insurers in accordance with the procedures set forth in each of the policies.  The
Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts
payable as a result of such action, suit, proceeding, inquiry or investigation in accordance with the terms of such policies.


 


e.       
Selection of Counsel .  In the event the Company shall be obligated hereunder to pay the Expenses of any Claim,
the Company shall be entitled to assume the defense of such Claim, with counsel reasonably approved by the applicable Indemnitee,
upon the delivery to such Indemnitee of written notice of its election to do so. After delivery of such notice, approval of such
counsel by the Indemnitee and the retention of such counsel by the Company, the Company will not be liable to such Indemnitee under
this Agreement for any fees of counsel subsequently incurred by such Indemnitee with respect to the same Claim; provided that,
(i) the Indemnitee shall have the right to employ such Indemnitee’s counsel in any such Claim at the Indemnitee’s expense;
(ii) the Indemnitee shall have the right to employ its own counsel in connection with any such proceeding, at the expense of the
Company, if such counsel serves in a review, observer, advice and counseling capacity and does not otherwise materially control
or participate in the defense of such proceeding; and (iii) if (A) the employment of counsel by the Indemnitee has been previously
authorized by the Company, (B) such Indemnitee shall have reasonably concluded that there is a conflict of interest between the
Company and such Indemnitee in the conduct of any such defense, or (C) the Company shall not continue to retain such counsel to
defend such Claim, then the fees and expenses of the Indemnitee’s counsel shall be at the expense of the Company.


 


 


11



    	 



    	 



    

 


 


3.        Additional
Indemnification Rights; Nonexclusivity.


 


a.       
Scope .  The Company hereby agrees to indemnify Indemnitee to the fullest extent permitted by law, even if such
indemnification is not specifically authorized by the other provisions of this Agreement or any other agreement, the Certificate,
the Company’s Bylaws or by statute. In the event of any change after the date of this Agreement in any applicable law, statute
or rule which expands the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, stockholder,
employee, controlling person, agent or fiduciary, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement
the greater benefits afforded by such change. In the event of any change in any applicable law, statute or rule which narrows the
right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, agent or fiduciary, such
change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect
on this Agreement or the parties’ rights and obligations hereunder except as set forth in Section 8(a) hereof.


 


b.       
Nonexclusivity .  Notwithstanding anything in this Agreement, the indemnification provided by this Agreement shall
be in addition to any rights to which Indemnitee may be entitled under the Certificate, the Company’s Bylaws, any agreement,
any vote of stockholders or disinterested directors, the laws of the State of Delaware, or otherwise. Notwithstanding anything
in this Agreement, the indemnification provided under this Agreement shall continue as to each Indemnitee for any action such Indemnitee
took or did not take while serving in an indemnified capacity even though the Indemnitee may have ceased to serve in such capacity
and such indemnification shall inure to the benefit of each Indemnitee from and after Indemnitee’s first day of service as
a director with the Company or affiliation with a director from and after the date such director commences services as a director
with the Company.


 


4.        No
Duplication of Payments .  The Company shall not be liable under this Agreement to make any payment in connection
with any Claim made against any Indemnitee to the extent such Indemnitee has otherwise actually received payment (under any insurance
policy, Certificate, Bylaws or otherwise) of the amounts otherwise indemnifiable hereunder.


 


5.        Partial
Indemnification .  If any Indemnitee is entitled under any provision of this Agreement to indemnification by the
Company for any portion of Expenses incurred in connection with any Claim, but not, however, for all of the total amount thereof,
the Company shall nevertheless indemnify Indemnitee for the portion of such Expenses to which such Indemnitee is entitled.


 


6.        Mutual
Acknowledgement .  The Company and each Indemnitee acknowledge that in certain instances, Federal law or applicable
public policy may prohibit the Company from indemnifying its directors, officers, employees, controlling persons, agents or fiduciaries
under this Agreement or otherwise.


 


7.        Liability
Insurance .  During any period of time any Indemnitee is entitled to indemnification rights under this Agreement,
the Company shall maintain liability insurance applicable to directors, officers, employees, control persons, agents or fiduciaries,
each Indemnitee shall be covered by such policies in such a manner as to provide Indemnitee the same rights and benefits as are
accorded to the most favorably insured of the Company’s directors, if such Indemnitee is a director, or of the Company’s
officers, if such Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, controlling
persons, agents or fiduciaries, if such Indemnitee is not an officer or director but is a key employee, agent, control person,
or fiduciary.  Said liability insurance shall provide coverage amounts of no less than those specified in Schedule A
attached hereto and be held with an insurance carrier which is the Board of Directors of the Company believes is of financial sound
condition.


 


8.        Exceptions
..  Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms
of this Agreement:


 


a.      Claims
Under Section 16(b).  To indemnify any Indemnitee for expenses and the payment of profits arising from the purchase and
sale by such Indemnitee of securities in violation of Section 16(b) of the Exchange Act or any similar successor statute;


 


b.      Unlawful
Indemnification.  To indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine
that such indemnification is not lawful;


 


c.      Fraud.  To
indemnify an Indemnitee if a final decision by a court having jurisdiction in the matter shall determine that the Indemnitee has
committed fraud on the Company; or


 


 


12



    	 



    	 



    




 


d.      Insurance.  To
indemnify any Indemnitee for which payment is actually and fully made to Indemnitee under a valid and collectible insurance policy.


 


9.        Period
of Limitations .  No legal action shall be brought and no cause of action shall be asserted by or in the right of
the Company against any Indemnitee, any Indemnitee’s estate, spouse, heirs, executors or personal or legal representatives
after the expiration of five (5) years from the date of accrual of such cause of action, and any claim or cause of action of the
Company shall be extinguished and deemed released unless asserted by the timely filing of a legal action within such five (5) year
period; provided, however, that if any shorter period of limitations is otherwise applicable to any such cause of action, such
shorter period shall govern.


 


10.    Construction of Certain
Phrases.


 


a.      For
purposes of this Agreement, references to the “Company” shall include, in addition to the resulting corporation, any
constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its directors, officers, employees, agents or fiduciaries,
so that if Indemnitee is or was or may be deemed a director, officer, employee, agent, control person, or fiduciary of such constituent
corporation, or is or was or may be deemed to be serving at the request of such constituent corporation as a director, officer,
employee, control person, agent or fiduciary of another corporation, partnership, joint venture, employee benefit plan, trust or
other enterprise, each Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting
or surviving corporation as each Indemnitee would have with respect to such constituent corporation if its separate existence had
continued.


 


b.      For
purposes of this Agreement, references to “other enterprises” shall include employee benefit plans; references to “fines”
shall include any excise taxes assessed on any Indemnitee with respect to an employee benefit plan; and references to “serving
at the request of the Company” shall include any service as a director, officer, employee, agent or fiduciary of the Company
which imposes duties on, or involves services by, such director, officer, employee, agent or fiduciary with respect to an employee
benefit plan, its participants or its beneficiaries; and if any Indemnitee acted in good faith and in a manner such Indemnitee
reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, such Indemnitee shall
be deemed to have acted in a manner “not opposed to the best interests of the Company” as referred to in this Agreement.


 


c.      For
purposes of this Agreement a “Change in Control” shall be deemed to have occurred if (i) any “person” (as
such term is used in Sections 13(d)(3) and 14(d)(2) of the Exchange Act), other than a trustee or other fiduciary holding securities
under an employee benefit plan of the Company or a corporation owned directly or indirectly by the stockholders of the Company
in substantially the same proportions as their ownership of stock of the Company, (A) who is or becomes the beneficial owner, directly
or indirectly, of securities of the Company representing 20% or more of the combined voting power of the Company’s then outstanding
Voting Securities, increases his beneficial ownership of such securities by 5% or more over the percentage so owned by such person,
or (B) becomes the “beneficial owner” (as defined in Rule 13d-3 under said Exchange Act), directly or indirectly, of
securities of the Company representing more than 30% of the total voting power represented by the Company’s then outstanding
Voting Securities, (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute
the Board of Directors of the Company and any new director whose election by the Board of Directors or nomination for election
by the Company’s stockholders was approved by a vote of at least two-thirds (2/3) of the directors then still in office who
either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease
for any reason to constitute a majority thereof, or (iii) the stockholders of the Company approve a merger or consolidation of
the Company with any other corporation other than a merger or consolidation which would result in the Voting Securities of the
Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into
Voting Securities of the surviving entity) at least two-thirds (2/3) of the total voting power represented by the Voting Securities
of the Company or such surviving entity outstanding immediately after such merger or consolidation, or the stockholders of the
Company approve a plan of complete liquidation of the Company or an agreement for the sale or disposition by the Company of (in
one transaction or a series of transactions) all or substantially all of the Company’s assets.


 


 


13



    	 



    	 



    




 


d.      For
purposes of this Agreement, “Independent Legal Counsel” shall mean an attorney or firm of attorneys, selected in accordance
with the provisions of Section 1(e) hereof, who shall not have otherwise performed services for the Company or any Indemnitee within
the last three (3) years (other than with respect to matters concerning the right of any Indemnitee under this Agreement, or of
other indemnitees under similar indemnity agreements).


 


e.      For
purposes of this Agreement, a “Reviewing Party” shall mean any appropriate person or body consisting of a member or
members of the Company’s Board of Directors or any other person or body appointed by the Board of Directors who is not a
party to the particular Claim for which Indemnitee is seeking indemnification, or Independent Legal Counsel.


 


f.      For
purposes of this Agreement, “Voting Securities” shall mean any securities of the Company that vote generally in the
election of directors.


 


11.           
Counterparts . This Agreement may be executed in one or more counterparts, each of which shall constitute an original.


 


12.           
Binding Effect; Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of and be enforceable
by the parties hereto and their respective successors, assigns, including any direct or indirect successor by purchase, merger,
consolidation or otherwise to all or substantially all of the business and/or assets of the Company, spouses, heirs, and personal
and legal representatives. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation
or otherwise) to all, substantially all, or a substantial part, of the business and/or assets of the Company, by written agreement
in form and substance satisfactory to each Indemnitee, expressly to assume and agree to perform this Agreement in the same manner
and to the same extent that the Company would be required to perform if no such succession had taken place.  This Agreement
shall continue in effect with respect to Claims relating to Indemnifiable Events regardless of whether any Indemnitee continues
to serve as a director, officer, employee, agent, controlling person, or fiduciary of the Company or of any other enterprise, including
subsidiaries of the Company, at the Company’s request.


 


13.           
Attorneys’ Fees . In the event that any action is instituted by an Indemnitee under this Agreement or under any liability
insurance policies maintained by the Company to enforce or interpret any of the terms hereof or thereof, any Indemnitee shall be
entitled to be paid all Expenses incurred by such Indemnitee with respect to such action if such Indemnitee is ultimately successful
in such action.  In the event of an action instituted by or in the name of the Company under this Agreement to enforce
or interpret any of the terms of this Agreement, the Indemnitee shall be entitled to be paid Expenses incurred by such Indemnitee
in defense of such action (including costs and expenses incurred with respect to Indemnitee counterclaims and cross-claims made
in such action), and shall be entitled to the advancement of Expenses with respect to such action, in each case only to the extent
that such Indemnitee is ultimately successful in such action.


 


14.           
Notice . All notices and other communications required or permitted hereunder shall be in writing, shall be effective when
given, and shall in any event be deemed to be given (a) five (5) days after deposit with the U.S. Postal Service or other applicable
postal service, if delivered by first class mail, postage prepaid, (b) upon delivery, if delivered by hand, (c) one business day
after the business day of deposit with Federal Express or similar overnight courier, freight prepaid, or (d) one day after the
business day of delivery by facsimile transmission, if deliverable by facsimile transmission, with copy by first class mail, postage
prepaid, and shall be addressed if to Indemnitee, at each Indemnitee’s address as set forth beneath the Indemnitee’s
signature to this Agreement and if to the Company at the address of its principal corporate offices (attention: Secretary) or at
such other address as such party may designate by ten (10) days’ advance written notice to the other party hereto.


 


 


14



    	 



    	 



    




 


15.           
Severability .  The provisions of this Agreement shall be severable in the event that any of the provisions hereof
(including any provision within a single section, paragraph or sentence) are held by a court of competent jurisdiction to be invalid,
void or otherwise unenforceable, and the remaining provisions shall remain enforceable to the fullest extent permitted by law.
Furthermore, to the fullest extent possible, the provisions of this Agreement (including, without limitations, each portion of
this Agreement containing any provision held to be invalid, void or otherwise unenforceable, that is not itself invalid, void or
unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.


 


16.           
Choice of Law .  This Agreement shall be governed by and its provisions construed and enforced in accordance with
the laws of the State of Delaware, as applied to contracts between Delaware residents, entered into and to be performed entirely
within the State of Delaware, without regard to the conflict of laws principles thereof.


 


17.           
Subrogation .  In the event of payment under this Agreement, the Company shall be subrogated to the extent of
such payment to all of the rights of recovery of Indemnitee who shall execute all documents required and shall do all acts that
may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights.


 


18.           
Amendment and Termination .  No amendment, modification, termination or cancellation of this Agreement shall be
effective unless it is in writing signed by the parties to be bound thereby.  Notice of same shall be provided to all
parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other
provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.


 


19.           
Corporate Authority .  The Board of Directors of the Company and its stockholders in accordance with Delaware
law have approved the terms of this Agreement.


 


(Remainder of page intentionally left blank)


 


 


15



    	 



    	 



    

 


 


IN WITNESS WHEREOF, the parties hereto have
executed this Indemnification Agreement on and as of the day and year first above written.


 


	 	APOLLO MEDICAL MANAGEMENT, INC.,
	 	a Delaware corporation
	 	 
	 	By: /S/ Warren Hosseinion, M.D.
	 	 
	 	“Indemnitees”
	 	 
	 	/S/ Adrian Vasquez, M.D.


 


 


16



    	 



    	 



    

 


 


Schedule A


 


The Company
agrees to have a minimum directors and officers insurance policy of $2 million.